Effect of Factor Xa Inhibitors on the Platelet-derived Microparticles Procoagulant Activity In Vitro> and In Vivo in Rats

Summary

The aim of this study was to investigate the effect of factor Xa inhibitors on the prothrombinase activity of platelet-derived microparticles in vitro and in vivo. The factor Xa inhibitors studied were DX9065A (a direct factor Xa inhibitor) and Sanorg34006 (an antithrombin (AT)-mediated factor Xa inhibitor). Microparticles formed from the platelet surface following activation were isolated by size exclusion gel chromatography. After purification, their presence was detected by their procoagulant activity and by flow cytometry. Our results show that factor Xa and/or factor Va were present at the surface of the platelet-derived microparticles. Prothrombinase formed on the microparticles was inhibited by factor Xa inhibitors at IC₅₀ values of 0.45 ± 0.05 and 0.045 ± 0.005 µM for DX9065A and AT-Sanorg34006 respectively. In an experiment aimed at determining the kinetics of microparticles formation we demonstrated that thrombin traces were sufficient to induce the formation of a significant quantity of microparticles. Both factor Xa inhibitors delayed the formation of microparticles by delaying thrombin generation. The thrombogenic effect of the microparticles were studied in vivo in a modified arterio-venous shunt model in the rat. In this model, the increase in the thrombus weigh due to microparticles or phospholipids did not differ significantly (33% and 23% respectively). In these conditions, prothrombinase activity seemed to play a lesser role in the thrombogenic effect than phospholipids. Nevertheless, factor Xa inhibitors were efficient and inhibited thrombus formation in a dose-dependent manner.

These results demonstrate that platelet-derived microparticles display a potent prothrombotic effect in vivo and show that factor Xa inhibitors are potent antithrombotic compounds when thrombosis was induced by microparticles.

Key words

Factor Xa - microparticles - platelets - Sanorg34006 - DX9065A

• References

• 1 Zwaal RFA, Comfurius P, Bevers EM. Platelet procoagulant activity and microvesicle formation. Its putative role in hemostasis and thrombosis. Biochim Biophys Acta 1992; 1180: 1-23.
• 2 Sims PJ, Faioni EM, Wiedmer T, Shattil SJ. Complement proteins C5b-9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptor for coagulation factor Va and express prothrombinase activity. J Biol Chem 1988; 263: 18205-12.
• 3 Sims PJ, Wiedmer T, Esmon CT, Weiss HJ, Shattil SJ. Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. Studies in Scott syndrome: an isolated defect in platelet procoagulant activity. J Biol Chem 1989; 264: 17049-57.
• 4 Widemer T, Shattil S, Cunningham M, Sims PJ. Role of calcium and calpain in complement-induced vesiculation of the platelet plasma membrane and in the exposure of the platelet factor Va receptor. Biochemistry 1990; 29: 623-32.
• 5 George JN, Pickett EB, Saucerman S. Platelet surface glycoproteins. Studies on resting and activated platelets and platelet membrane microparticles in normal subjects, and observations in patients during adult respiratory distress syndrome and cardiac surgery. J Clin Invest 1986; 78: 340-8.
• 6 Holme PA, Brosstad F, Solum NO. The difference between platelet and plasma FXIII used to study the mechanism of platelet microvesicle formation. Thromb Haemost 1993; 70: 681-6.
• 7 Holme PA, Solum NO, Brosstad F, Roger M, Abdlenoor M. Demonstration of platelet-derived microvesicles from patients with activated coagulation and fibrinolysis using a filtration technique and Western blotting. Thromb Haemost 1994; 72: 666-71.
• 8 Jy W, Horstman LL, Arce M, Ahn YS. Clinical significance of platelet microparticles in autoimmune thrombocytopenias. J Lab Clin Med 1992; 119 (04) 331-2.
• 9 Khan I, Zucker-Francklin D, Karpatkin M. Microthrombocytosis and platelet fragmentation associated with idiopathis/autoimmune thrombosytopenic prutpura. Br J Haematol 1975; 31: 449-60.
• 10 Abrams CS, Ellison N, Budzynski A, Shattil SJ. Direct detection of activated platelet and platelet-derived microparticles. Blood 1990; 75: 128-38.
• 11 Holme PA, Brosstad F, Solum NO. Platelet-derived microvesicles and activated platelet express factor Xa activity. Blood Coag Fibrinol 1995; 06: 302-10.
• 12 Nieuwland R, Berkmans RJ, Rotteveeleijkman RC, Maquelin KN, Roozendaal KJ, Jansens PGM, Tenhave K, Eijsman L, Hack CE, Sturk P. Cell-derived microparticles generated in patients during cardiopulmonary bypass are highly procoagulant. Circulation 1997; 96: 3534-41.
• 13 Herbert JM, Hérault JP, Bernat A, van Amsterdam RGM, Lormeau JC, Petitou M, van Boeckel C, Hoffmann P, Meuleman DG. Biochemical and pharmacological properties of Sanorg 34006, a potent and long-acting synthetic pentasaccharide. Blood 1998; 91 (11) 4197-205.
• 14 Hara T, Kunitada S, Iwamoto M. DX-9065A, a synthetic and selective factor Xa inhibitor; species difference in its anticoagulant activity. Thromb Haemost 1993; 69: 890-8.
• 15 Hara T, Yokoyama A, Tanabe K, Ishihara H, Iwamoto M. DX-9065a, an orally active, specific inhibitor of factor Xa, inhibits thrombosis without affecting bleeding time in rats. Thromb Haemost 1995; 74: 635-9.
• 16 Herbert JM, Bernat A, Dol F, Hérault JP, Crépon B, Lormeau JC. DX-9065A a novel, synthetic, selective and orally active inhibitor of factor Xa. In vitro and in vivo studies. J Pharmacol Exp Ther 1996; 276: 1030-8.
• 17 Yano Y, Shiba E, Kambayashi JI, Sakon M, Kawasakit P. The effects of calpeptin (a calpain specific inhibitor) on agonist induced microparticles formation from the platelet plasma membrane. Thromb Res 1993; 71: 385-96.
• 18 Fox JEB, Austin CD, Reynols CC, Steffen PK. Evidence that agonist induced activation of calpain causes the shedding of procoagulant containing microvesicles from the membrane of aggregating platelets. J Biol Chem 1991; 266: 13289-95.
• 19 Beguin S, Lindhout T, Hemker HC. The effect of trace amounts of tissue factor on thrombin generation in platelet rich plasma, its inhibtition by heparin. Thromb Haemost 1989; 61: 25-9.
• 20 Peyrou V, Lormeau JC, Hérault JP, Boneu B, Herbert JM. Long term persistence of low molecular weight material with anti-factor Xa activity contributes to the anticoagulant and antithrombotic effects after subcutaneous injection of CY 216 in the rabbit. Blood Coag Fibrinol 1997; 08: 175-84.
• 21 Jy WC, Horstman LL, Wang F, Duncan RC, Ahn YS. Platelet factor 3 in plasma fractions – its relation to microparticle size and thromboses. Thromb Res 1995; 80: 471-82.
• 23 Umetsu T, Sanai K. Effect of KC-6141, an anti-aggregating compound, on experimental thrombosis in rats. Thromb Haemost 1978; 39: 74-83.
• 24 Dachary-Prigent J, Freyssinet JM, Pasquet JM, Carron JC, Nurden A. Annexin V as a probe of aminophospholipid exposure and platelet membrane vesiculation: a flow cytometry study showing a role for free sulfydryl groups. Blood 1993; 81: 2554-65.
• 25 Gilbert GE, Sims JS, Wiedmer T. Platelet-derived microparticles express high affinity receptors for factor VIII. J Biol Chem 1991; 266: 17261-8.
• 26 Monkovic DD, Tracy PB. Functional characterization of human plateletreleased factor V and its activation by factor Xa and thrombin. J Biol Chem 1990; 265: 17132-40.
• 27 Hérault JP, Bernat A, Pflieger AM, Lormeau JC, Herbert JM. Comparative effects of two direct and indirect factor Xa inhibitors on free and clot-bound prothrombinase. J Pharmacol Exp Ther 1997; 283: 16-22.
• 28 Hoffman M, Monroe DM, Roberts H. Coagulation factor Xa binding to activated platelets and platelet-derived microparticles: A flow cytometric study. Thromb Haemost 1992; 68: 74-8.
• 29 Reverter JC, Beguin S, Kessels R, Hemker HC, Coller BS. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. J Clin Invest 1996; 98: 863-74.